Hosted on MSN1mon
Bristol Myers announces FDA approval of Opdivo Qvantig injection
Bristol Myers (BMY) Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human ...
Zacks.com on MSN10d
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...
Cancer Research UK4y
A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study)
This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...
precisionmedicineonline7d
Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.